Cell-based vaccines can be derived from autologous or allogeneic human cancer cell lines or tumor lysates, either loaded on dendritic cells or administered in adjuvants to promote dendritic cell activation in order to stimulate specific CD8+ and CD4+ T cell responses [7]. This evidence concerns the gene CD4 and cancer.